Zhejiang-based Keyi Pharma Inks Landmark $2.1B Global License-Out Deal for First-in-Class BCMA/CD19 Dual-Target CAR-T Therapy KQ-2003

Large summit in August, scan to register, review takes time

Note:This article does not constitute any investment opinions or recommendations., subject to official/company announcements;This article is only for the introduction of medical and health-related drugs.，Non-therapeutic recommendations (if any) do not represent the platform's position.

PharmaCircleLearned:Recently, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. ("Novatim") has entered into a strategic collaboration with U.S.-based ERIGEN LLC. Both parties have signed an exclusive out-licensing agreement covering the overseas rights to KQ-2003, Novatim's innovative, world-first dual-targeting CAR-T cell therapy product with a parallel-enhanced design targeting BCMA/CD19. This collaboration encompasses global rights outside Greater China (excluding India, Turkey, and Russia), granting ERIGEN exclusive development, registration, and commercialization rights in the relevant regions. Additionally, the agreement authorizes ERIGEN LLC to utilize the core patent structure and sequences of KQ-2003 to develop an "off-the-shelf CAR-T cell therapy." According to the terms of the agreement, Novatim will retain all rights to this off-the-shelf product within Greater China.

According to the BD deal agreement: Novatim will receive$15 millionThe recent development milestone payment, with the potential to receive up to $1.32 billion in subsequent R&D, registration, and commercialization milestone payments. Meanwhile, Novatim will also receive sales royalties of up to $800 million based on the net sales of KQ-2003 in the authorized region.

Recommendation

In early August, PharmaCircle held in-depth discussions on the cutting-edge innovations of three major hot drugs: ADC, RDC, and PDC, jointly exploring new development paths for this revolutionary technology from the laboratory to clinical applications, and from China to the world.

Welcome to click the mini program below to register for free.

◈ 09:00-09:30

TBD

◈ 09:30-10:00

Next-Generation Topo1 Inhibitor - Solving the Challenge of Resistance to Existing Targeted Drugs and ADCs
Qin Gang
Founder, Chairman and Chief Executive Officer of QuidMed

◈ 10:00-10:30

Exploration of Extracellular Lysis ADC Technology and Partial Clinical Development Product Layout

Cai Jiaqiang

Co-Founder, Co-CEO & CSO of Suzhou Novatim

◈ 10:30-11:00

Subject to be determined
Yang Xiugao

CSPC Group, Senior Medical Director

◈ 11:00-11:30

Development of Anti-Tumor Albumin-Conjugated Drugs

Sun Lichun

Taierkang Bio, Founder

◈ 11:30-12:10

Panel: Leading International Advances in Chinese Solid Tumor Clinical Trials

[ Host ]

Yang Xiugao  CSPC Group, Senior Medical Director

[ Guest ]

Zuo YunxiaBeiGene, Vice President, Head of Gastrointestinal Diseases

Gao ChangshouAilis Pharmaceutical, Chief Technology Officer

◈ 12:10-13:30

Lunch Break

◈ 13:30-14:00

Clinical Research and Technological Innovation of ACR246, the World's First 5T4-ADC

Miao Zhenwei

Chairman and CEO of Yingbai Rui

◈ 14:00-14:30

Guest Topic Confirmation in Progress

Liu Dong

Andaopharma, CEO

◈ 14:30-15:00

Guest Itinerary Confirmation in Progress

◈ 15:00-15:30

Current Status and Differentiated Innovation of ADC Drug Development
Wu Youling
Founder and CEO of Mylex Bio

◈ 15:30-16:00

ADC Drug Development Iteration Strategy

Yan Bin

Head of MedChem ADC Platform

◈ 09:00-09:30

Advances and Prospects in the Development of New Technologies for Tumor-Targeted Radiopharmaceuticals (Proposed)
Yiqin Wu
Novatim, Chief Scientific Officer

◈ 09:30-10:00

Application of Low-Dose Radiopharmaceuticals in Non-Oncology Fields
Deng Qimin
Yunket Pharmaceuticals, CEO

◈ 10:00-10:30

Research on Radiopharmaceuticals Based on Peptides and Nanobodies

Hao Hong

Sitikang Chen, CTO & Founder

◈ 10:30-11:00

Mechanism of Action and Structural Design of Radiopharmaceuticals

Single Wave

Bioray Creation, CEO

◈ 11:00-11:30

Prospects for the Development of Terbium-161 Radionuclide Research

Kong Xiangsheng
Chief Scientist of Medinno Medical

◈ 11:30-12:00

Subject to be determined

Han Zhihao
Youth Committee Member of the Chinese Optical Society, Radiation Protection Officer at the School

◈ 12:00-13:30

Lunch Break

◈ 13:30-14:00

Subject to be determined

Bai Ge
Novatim, CEO

◈ 14:00-14:30

Subject to be determined

◈ 14:30-15:00

Design of Dosing Regimens Based on Radiation Dosimetry

Zhang Xiaoxia

◈ 15:00-15:30

Progress of MB0151, a PDC Drug Targeting SSTR-2

Liang Guangjun

Mainstream Source Biotechnology Co., Ltd., Non-Clinical Director

*The above schedule and guests are being updated, subject to the actual situation on site.